Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.
ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)
Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.
Treatment strategies for patients with lower-risk MDS are examined.
In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
